Revvity (RVTY) AI Stock Analysis

• Market Cap: $10.61B
• Dividend Yield: 0.31%
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): 38.8
• Beta (1Y): 0.72
• Revenue Growth: 3.33%
• EPS Growth: 32.86%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.18
• Shares Outstanding: 116,072,580
• 10 Day Avg. Volume: 1,116,139
• 30 Day Avg. Volume: 1,415,977
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 4.96
• Enterprise Value/Gross Profit: 8.87
• Enterprise Value/Ebitda: 16.87
• 1Y Price Target: $112.73
• Price Target Upside: 25.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 64 Neutral
• Price Target: $96.00 ▲(7.06% Upside)

Revvity's overall stock score reflects a stable financial performance with strong cash flows and a solid balance sheet. However, the high P/E ratio suggests overvaluation, and technical indicators show bearish trends. The earnings call highlighted both growth opportunities and significant challenges, particularly in the diagnostics segment in China, impacting future guidance.

Positive Factors

Cost Management

RVTY is taking additional cost actions to help offset margin pressures, allowing it to enter the future with a 28% operational margin baseline, which management expects to expand further.

Resilience and Risk Mitigation

Revvity's transformed portfolio is expected to be resilient through ongoing market turbulence, with limited exposure to NIH uncertainty reducing risk.

Software Performance

Software, accounting for 7% of revenue, grew approximately 30%, driving a significant portion of growth.

Negative Factors

China Policy Impact

China policy changes have rapidly impacted high-margin multiplex tests, reducing confidence in the China ImmunoDx business.

Guidance and Market Reaction

RVTY shares closed down 9% due to a guidance cut, with both organic growth and EPS lowered.

Tariff Challenges

Life Sciences products face high China tariffs, requiring supply chain rework, which poses a headwind to top-line growth.

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Revvity generates revenue through multiple streams, including subscription fees for its software products, licensing agreements for its technology, and consulting services that support the implementation and optimization of its solutions. The company also engages in partnerships with other technology firms and industry leaders to expand its market reach and enhance its service offerings. Key revenue drivers include the growth of its customer base, the increasing demand for data-driven decision-making tools, and the continued investment in AI and machine learning technologies, which create ongoing opportunities for upselling and cross-selling additional services.

Revvity Financial Statement Overview

Summary

Revvity presents a stable financial profile with steady margins and a solid balance sheet. Despite some pressure on profitability and revenue growth, the company maintains strong operational cash flows and a healthy equity base.

Income Statement

Revvity's income statement shows moderate performance with a positive Gross Profit Margin of 55.93% and a decent Net Profit Margin of 10.19% for TTM. However, the company is facing challenges in revenue growth, with a slight increase of 1.58% from the previous year. EBIT Margin is satisfactory at 13.58%, although EBITDA Margin has decreased to 25.68% from last year's 30.50%.

Balance Sheet

The balance sheet reveals a stable financial position with a Debt-to-Equity Ratio of 0.45, indicating manageable leverage. Return on Equity (ROE) is moderate at 3.77% for TTM, reflecting a decrease in profitability compared to previous years. The Equity Ratio stands at a robust 61.11%, suggesting strong financial stability.

Cash Flow

Cash flow from operations is healthy, with an Operating Cash Flow to Net Income Ratio of 2.07, indicating efficient conversion of income into cash. However, Free Cash Flow declined by 6.05% from the previous year, and the Free Cash Flow to Net Income Ratio is 1.78, suggesting room for improvement in cash generation relative to income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.80B	2.76B	2.75B	3.31B	3.83B	2.66B
Gross Profit	1.57B	1.54B	1.54B	1.99B	2.43B	1.74B
EBITDA	822.61M	840.25M	713.56M	1.18B	1.62B	1.07B
Net Income	285.20M	270.38M	693.09M	569.18M	943.16M	727.89M
Balance Sheet
Total Assets	12.36B	12.39B	13.56B	14.13B	15.00B	7.96B
Cash, Cash Equivalents and Short-Term Investments	991.85M	1.16B	1.60B	454.36M	603.32M	402.04M
Total Debt	3.37B	3.33B	4.07B	4.60B	5.16B	2.22B
Total Liabilities	4.81B	4.73B	5.69B	6.75B	7.86B	4.22B
Stockholders Equity	7.56B	7.67B	7.87B	7.38B	7.14B	3.74B
Cash Flow
Free Cash Flow	508.91M	541.65M	9.90M	594.18M	1.32B	814.67M
Operating Cash Flow	590.53M	628.30M	91.27M	679.81M	1.41B	892.18M
Investing Cash Flow	656.98M	776.16M	1.31B	-132.85M	-4.11B	-504.50M
Financing Cash Flow	-1.53B	-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 89.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Negative. The current price of 89.67 is below the 20-day moving average (MA) of 90.19, below the 50-day MA of 94.41, and below the 200-day MA of 104.78, indicating a bearish trend. The MACD of -1.23 indicates Negative momentum. The RSI at 46.00 is Neutral, neither overbought nor oversold. The STOCH value of 82.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	80 Outperform	$12.98B	34.63	89.38%	―	9.94%	25.30%
QGEN	74 Outperform	$10.65B	28.79	10.81%	2.55%	5.15%	412.41%
DGX	70 Neutral	$20.44B	21.86	13.65%	1.68%	12.58%	13.00%
NTRA	70 Neutral	$21.98B	―	-24.32%	―	44.38%	22.87%
ILMN	65 Neutral	$15.62B	12.77	68.11%	―	-3.32%	―
RVTY	64 Neutral	$10.61B	38.79	3.61%	0.31%	3.33%	32.86%
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%

Revvity Corporate Events

Revvity to Announce Q4 and Full-Year 2024 Results

Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.